Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Paragon Biomedical | INDUSTRY |
| invivodata, Inc. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to examine the impact of intradermal delivery of NP2 on pain scores and pain medication usage in subjects with intractable pain due to malignant disease. A second purpose is to confirm safety and secondary efficacy measurements.
Chronic severe pain remains a significant unmet medical need in patients that have progressive cancer. Existing treatments have limited efficacy and also suffer significant side effects. This is a multi-center, randomized, double blind, placebo-controlled clinical trial designed to evaluate the impact of intradermal injection of NP2 in subjects who have intractable pain due to malignant disease. NP2 is a gene transfer vector engineered to express human preproenkephalin, a gene naturally involved in pain control. Delivery of NP2 directly to the site of pain caused by cancer is intended to provide increased Enkephalin peptides, which bind to opioid receptors, that may allow better pain control.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Active NP2 | Experimental | Single intradermal dose of active NP2. An open label study extension will offer up to two additional doses of active NP2 between weeks 4-10 following the previous dose. |
|
| Placebo | Placebo Comparator | Single intradermal dose of placebo (vehicle). An open label study extension will offer up to two additional doses of active NP2 between weeks 4-10 following the previous dose. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| NP2 | Biological | NP2 is a replication defective HSV-1 based gene transfer vector engineered to express human preproenkephalin. The drug will be injected intradermally corresponding to the distribution of the malignancy-related pain. The total amount to be injected will be a dose volume of 1.0 ml delivered in a single session on Study Day 0. |
| Measure | Description | Time Frame |
|---|---|---|
| Pain Measured by the Numerical Rating Scale (NRS) | • Change from baseline of the average daily NRS pain score (scale of 0 to 10 ) of Placebo compared to Active NP2 cohorts. | Days -5 to -1 predosing and days 3 to 14 postdosing |
| Measure | Description | Time Frame |
|---|---|---|
| Opioid Pain Medication Usage Morphine Equivalent Units (MEU) | •Change from baseline of use of opioid pain medication average daily MEU of Placebo compared to Active NP2 cohorts | Days -5 to -1 predosing and 3 to 14 postdosing |
| Quality of Life ECOG |
Not provided
Main Inclusion Criteria:
Main Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Darren Wolfe, Ph.D. | Diamyd Inc | Study Director |
| David Fink, M.D. | University of Michigan | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| HOPE Research Institute | Phoenix | Arizona | 85050 | United States | ||
| Arizona Clinical Research Center |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Placebo | Biological | The placebo (vehicle) will be injected intradermally corresponding to the distribution of the malignancy-related pain. The total amount to be injected will be a dose volume of 1.0 ml delivered in a single session on Study Day 0. |
|
•Quality of Life measured by Eastern Cooperative Oncology Group Performance Status (ECOG) assessment at follow-up visits compared to baseline of Placebo compared to Active NP2 cohorts.
| Baseline and Week 1, 2 and 4 |
| Quality of Life SF-12 | •Quality of Life measured by the 12-Item Short Form Health Survey (SF-12v2) at follow-up visits compared to baseline of Placebo compared to Active NP2 cohorts. | Baseline and Week 1, 2 and 4 |
| Pain SF-MPQ | •Short Form McGill Pain Questionnaire (SF-MPQ-2) assessment at follow-up visits compared to baseline of Placebo compared to Active NP2 cohorts | Baseline and Week 1, 2 and 4 |
| Tucson |
| Arizona |
| 85715 |
| United States |
| Compassionate Cancer Care Medical Group, Inc. | Corona | California | 92879 | United States |
| Cancer Care Associates | Fresno | California | 93720 | United States |
| TriWest Research Associates | La Mesa | California | 91942 | United States |
| White Memorial Medical Center | Los Angeles | California | 90033 | United States |
| Hematology Oncology Associates | Oakland | California | 94609 | United States |
| Advanced Pharma CR | Miami | Florida | 33175 | United States |
| Better Health Clinical Research Inc | Newnan | Georgia | 30265 | United States |
| Christie Clinic | Champaign | Illinois | 61820 | United States |
| Global Scientific Innovations | Evansville | Indiana | 47714 | United States |
| Montana Cancer Institute Foundation | Missoula | Montana | 59802 | United States |
| Center for Clinical Research | Winston-Salem | North Carolina | 27103 | United States |
| Signal Point Clinical research Center | Middletown | Ohio | 45042 | United States |
| Pain Research of Oregon | Eugene | Oregon | 97401 | United States |
| Hematology Oncology Associatesof Rhode Island | Cranston | Rhode Island | 02920 | United States |
| Medical Therapy and Research | San Antonio | Texas | 78217 | United States |
| Medical Oncology Associates | Spokane | Washington | 99208 | United States |
| ID | Term |
|---|---|
| D010148 | Pain, Intractable |
| D009369 | Neoplasms |
| D010146 | Pain |
| ID | Term |
|---|---|
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided